KR950000664A - 신규한 13,14-디히드로-피지에프 2 베타(PGF2β) 및 이의 이소프로필 에스테르 - Google Patents
신규한 13,14-디히드로-피지에프 2 베타(PGF2β) 및 이의 이소프로필 에스테르 Download PDFInfo
- Publication number
- KR950000664A KR950000664A KR1019940013088A KR19940013088A KR950000664A KR 950000664 A KR950000664 A KR 950000664A KR 1019940013088 A KR1019940013088 A KR 1019940013088A KR 19940013088 A KR19940013088 A KR 19940013088A KR 950000664 A KR950000664 A KR 950000664A
- Authority
- KR
- South Korea
- Prior art keywords
- dihydro
- compound
- pgf2β
- general formula
- formula
- Prior art date
Links
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 title claims abstract 4
- PXGPLTODNUVGFL-JZFBHDEDSA-N prostaglandin F2beta Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-JZFBHDEDSA-N 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 3
- 239000001257 hydrogen Substances 0.000 claims abstract 3
- 208000010412 Glaucoma Diseases 0.000 claims abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 6
- 229920000858 Cyclodextrin Polymers 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- -1 isopropyl ester Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008016 pharmaceutical coating Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
본 발명은 낮은 농도에서 안압 강하 활성을 지니며, 자극성이 적어서 녹내장의 예방 및/또는 치료제로서 유용한 하기 일반식(Ⅰ)의 13,14－디히드로－프로스타글란딘 F2β및 이의 이소프로필 에스테르에 관한 것이다:
상기 식에서, R1은 수소 또는 이소프로필이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (7)
- 하기 일반식(Ⅰ)의 13,14－디히드로－프로스타글란딘(PG) F2β 또는 이의 이소프로필 에스테르 또는 이의 시클로덱스트린 클라트레이트 또는 R1이 수소인 경우, 이의 약학적 허용 염:상기 식에서, R1은 수소 또는 이소프로필이다.
- 제 1 항에 있어서, 13,14－디히드로－PGF2β 이소프로필 에스테르인 화합물.
- 제 1 항에 있어서, 13,14－디히드로－PGF2β인 화합물.
- 산성 조건하에서 하기 일반식(Ⅱ)의 화합물을 가수분해시키는 것을 특징으로 하는 하기 일반식(IB)의 13,14－디히드로－프로스타글란딘 F2β 이소프로필 에스테르의 제조방법:상기 식에서, THP는 테트라히드로피란－2－일이고, TBDMS는 t－부틸디메틸실릴이다.
- 알칼리 조건하에서 하기 일반식(IB)의 화합물을 가수분해시키는 것을 특징으로 하는 하기 일반식(IA)의 13,14－디히드로－프로스타글란딘 F2β의 제조방법:
- 활성 성분으로서 제 1 항에 나타낸 유효량의 일반식(Ⅰ)의 화합물 또는 이의 약학적 허용 염 또는 이의 시클로덱스트린 클라트레이트와 약학적 담체 또는 코팅물을 포함하는 약학적 조성물.
- 제 1 항에 나타낸 유효량의 일반식(Ⅰ)의 화합물 또는 이의 약학적 허용 염 또는 이의 시클로덱스트린 클라트레이트를 투여하는 것을 포함하는 녹내장의 예방 및/또는 치료에 사용하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP93-167531 | 1993-06-14 | ||
| JP16753193 | 1993-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR950000664A true KR950000664A (ko) | 1995-01-03 |
Family
ID=15851427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019940013088A KR950000664A (ko) | 1993-06-14 | 1994-06-10 | 신규한 13,14-디히드로-피지에프 2 베타(PGF2β) 및 이의 이소프로필 에스테르 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0628545A1 (ko) |
| KR (1) | KR950000664A (ko) |
| CN (1) | CN1106385A (ko) |
| CA (1) | CA2125804A1 (ko) |
| FI (1) | FI942785A (ko) |
| NO (1) | NO942212L (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100158D0 (sv) * | 2001-01-19 | 2001-01-19 | Synphora Ab | Novel method and composition for local treatment of Meniere´s disease and tinnitus |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4311707A (en) * | 1979-02-12 | 1982-01-19 | American Cyanamid Company | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions |
| US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
| SE8703854D0 (sv) * | 1987-10-07 | 1987-10-07 | Pharmacia Ab | Prostaglandinderivat for behandling av glaukom eller okuler hypertension |
| ES2113942T3 (es) * | 1990-12-10 | 1998-05-16 | Allergan Inc | Derivados de la homo-prostaglandina como hipotensores oculares. |
-
1994
- 1994-06-10 KR KR1019940013088A patent/KR950000664A/ko not_active Application Discontinuation
- 1994-06-13 FI FI942785A patent/FI942785A/fi not_active Application Discontinuation
- 1994-06-13 NO NO942212A patent/NO942212L/no unknown
- 1994-06-14 CA CA002125804A patent/CA2125804A1/en not_active Abandoned
- 1994-06-14 CN CN94108881A patent/CN1106385A/zh active Pending
- 1994-06-14 EP EP94304299A patent/EP0628545A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0628545A1 (en) | 1994-12-14 |
| FI942785A0 (fi) | 1994-06-13 |
| FI942785A (fi) | 1994-12-15 |
| CA2125804A1 (en) | 1994-12-15 |
| CN1106385A (zh) | 1995-08-09 |
| NO942212L (no) | 1994-12-15 |
| NO942212D0 (no) | 1994-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5510383A (en) | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension | |
| FI902258A0 (fi) | Menetelmä farmakologisesti aktiivisten 13,14-dihydro-17-fenyyli-18,19,20-trinor-PGF2 -alkyyliestereiden valmistamiseksi | |
| ATE165237T1 (de) | Starkschaumende orale zusammensetzung | |
| IL120317A0 (en) | Otic antibacterial compositions | |
| AU3126695A (en) | Immunological activity of rhamnolipids | |
| ATE157245T1 (de) | Kosmetisches präparat | |
| CA2150287A1 (en) | Agent for treating hepato-biliary diseases | |
| EP1501530B1 (en) | Prostaglandin f2 alpha analogs in combination with antimicrobial for treating glaucoma | |
| AU4272696A (en) | Non-beta-oxidizable fatty acid analogues, their uses as therpeutic active medicaments, and preparation thereof | |
| SE8801513D0 (sv) | Farmaceutisk komposition | |
| EP0283151A3 (en) | Prostaglandins useful for lowering intraocular pressure | |
| DE69430538D1 (de) | 2-azylalkyl-oder arylalenyl-cyclopentanheptan-und heptensäuren, derivate und therapeutische anwendung | |
| PT630252E (pt) | Preparacao farmaceutica baseada em ramnolipido contra doencas dermatologicas | |
| EP0667160B1 (en) | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension | |
| ES2045124T3 (es) | Un proceso para la preparacion de una composicion antitrombotica. | |
| KR950000664A (ko) | 신규한 13,14-디히드로-피지에프 2 베타(PGF2β) 및 이의 이소프로필 에스테르 | |
| IE801402L (en) | Gastric acid neutralizing agents | |
| US5627209A (en) | Use of certain 9-haloprostaglandins to treat glaucoma and ocular hypertension | |
| KR950032113A (ko) | 프로스타글란딘 에프 에스테르 | |
| KR900701278A (ko) | 바이러스 감염 치료용 담즙산 | |
| KR960703843A (ko) | 아실페닐글리신 유도체 및 그 화합물을 유효성분으로 하는, 콜라게나제 활성증진에 기인한 질환의 예방 및 치료 제(acylphenylglycine derivative and preventive and remedy for diseases caused by increased collagenase activity containing said compound as active ingredient) | |
| EP0228314A3 (en) | Use of ethanol/amine derivatives in treating or preventing hyperlipemia | |
| KR870006081A (ko) | 신규 16,17-아세탈치환 프레그난 21-오익 에시드유도체 및 그의 제조방법 | |
| KR950702412A (ko) | 항 hiv제 | |
| KR910000786A (ko) | 콜레스타디엔 유도체, 이의 제조방법 및 HMG-CoA 환원제를 저해하는 작용을 하는 약제로서의 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |